UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 19, 2005
Impax Laboratories, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 0-27354 65-0403311
- ---------------------------------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)
30831 Huntwood Ave., Hayward, CA 94544
- ---------------------------------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 476-2000
--------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 REGULATION FD DISCLOSURE
On July 19, 2005, the U.S. Patent and Trademark Office issued U.S. Patent
#6,919,373 to Alza Corporation (Alza) with claims covering its Concerta(R)
product. Concerta(R) is a registered trademark of Alza Corporation. This patent
was listed in the Food and Drug Administration's (FDA) Electronic Orange Book
(Orange Book) on July 19, 2005 and was the first time a patent relating to
Concerta(R) had been listed in the Orange Book. On July 19, 2005, we filed a
certification under Paragraph IV of the Hatch-Waxman Amendments with the FDA
relating to this patent and notified Alza and related companies of such
certification.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMPAX LABORATORIES, INC.
Date: July 29, 2005 By: /s/ Arthur A. Koch, Jr.
------------------------------
Name: Arthur A. Koch, Jr.
Title: Chief Financial Officer
3